All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-06-17T09:21:01.000Z

EHA 2019 | Why does FLT3 testing need to be performed?

By Emily Smith, Jorge Sierra
Featured
Jorge Sierra
Jun 17, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Jorge Sierra from Hospital de la Santa Creu i Sant Pau, Barcelona, ES, talks about the need to perform FLT3 testing in patients with AML.

Jorge Sierra describes how FLT3 mutations are one of the most common molecular abnormalities in acute myeloid leukemia (AML). He stresses the importance of testing patients for FLT3 mutations because there are FLT3-targeting agents available, such as midostaurin, and because the presence of FLT3 internal tandem duplication (FLT3-ITD) confers an adverse prognosis.

Why does FLT3 testing need to be performed?

More about...
AML-related mutationsASXL1CEBPAChromosomal aberrationsCore binding factorEHA 2019FLT3-ITDFLT3-TKDGilteritinibMidostaurinQuizartinibRUNX1TP53

Related articles

Add bookmark

SOHO 2019 | FLT3 inhibitors in AML

At the 2019 meeting of the Society of Hematologic Oncology (SOHO), Catherine Smith of the University of California San Francisco, US, discussed therapeutic targeting of FLT3 in AML, presenting the current landscape...

Oct 21, 2019
Add bookmark

SOHO 2019 | FLT3 inhibitors in AML

At the 2019 meeting of the Society of Hematologic Oncology (SOHO), Catherine Smith of the University of California San Francisco, US, discussed therapeutic targeting...

Oct 21, 2019
Add bookmark

Prof. Eduardo Rego | ASH 2017 | Take home message to Brazil from ASH 2017

59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA Professor Eduardo Rego University of São Paulo, São Paulo, BR

Dec 20, 2017
Add bookmark

Prof. Eduardo Rego | ASH 2017 | Take home message to Brazil from ASH 2017

59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA Professor Eduardo Rego University of São Paulo, São...

Dec 20, 2017

Newsletter

Subscribe to get the best content related to AML delivered to your inbox